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verified successfully. After the normal DNA of the affected 
family members was analyzed for the presence of the 212 
potential germline variants and subsequently the respective 
tumors, only one potential germline variant in MSX1 (chr4: 
4861985 T > G, c.359T > G, p.V120G, NM_002448) showed 
loss of the wild type allele in the tumor DNAs of the affected 
family members. A germline variant in MSX1 was identified 
in a Dutch family with clustering of Barrett’s esophagus and 
esophageal adenocarcinoma. This finding indicates that the 
germline defect in MSX1 may be associated with Barrett’s 
esophagus and cancer in this particular family.
Keywords Barrett’s esophagus · Esophageal 
adenocarcinoma · Familial clustering · Exome sequencing · 
Genetic testing
Introduction
Esophageal adenocarcinoma (EAC) is a histopathological 
subtype of esophageal cancer, of which the incidence is ris-
ing rapidly over the last decades in Western countries [1–3]. 
The presence of Barrett’s esophagus (BE), as a consequence 
of chronic gastro-esophageal reflux (GER), is generally 
accepted as the predominant risk factor of EAC. Other risk 
factors are high age, male gender, Caucasian ethnicity [4], 
and obesity [5]. The risk of developing EAC from BE is 
estimated at 0.12–0.5% per year [6, 7] and follows a mul-
timorphological sequence, in which metaplasia evolves to 
low-grade dysplasia (LGD), high-grade dysplasia (HGD) 
and ultimately into invasive adenocarcinoma [8].
Although the vast majority of BE and EAC cases are 
sporadic and caused by somatic mutations, over the last 
decades several families have been identified with cluster-
ing of BE and EAC [9–12]. Previous studies introduced 
Abstract The vast majority of esophageal adenocarci-
noma cases are sporadic and caused by somatic mutations. 
However, over the last decades several families have been 
identified with clustering of Barrett’s esophagus and esopha-
geal adenocarcinoma. This observation suggests that one 
or more hereditary factors may play a role in the initiation 
of Barrett’s esophagus and esophageal adenocarcinoma in 
these families. A Dutch family with clustering of Barrett’s 
esophagus and esophageal adenocarcinoma was identified. 
Normal DNA obtained from the proband diagnosed with 
Barrett’s esophagus was analyzed with SNP array and exome 
sequencing. A custom-made panel consisting of potential 
germline variants was verified in the normal DNA of the 
affected family members. In addition, the respective tumors 
were analyzed for somatic loss of the wild type allele or the 
presence of an inactivating somatic mutation in the wild type 
allele. Exome sequencing revealed 244 candidate variants in 
the normal DNA of the proband, of which 212 variants were 
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the definition familial BE (FBE), i.e. two or more first- 
or second-degree family members diagnosed with BE or 
EAC. It has been estimated that approximately 7% of BE 
and EAC cases are considered familial [13–15]. When 
compared to sporadic cases, familial cases of BE and EAC 
are mostly diagnosed at a younger age [14–16]. It can be 
hypothesized that the initiation of BE and EAC in several 
members of one family is caused by the presence of one 
or more inherited factors. The pattern of inheritance of 
most familial cancer syndromes is based on the concept 
of “Knudsons two hit” hypothesis, causing a phenotypic 
dominant inheritance pattern, i.e. biallelic inactivation of 
a tumor suppressor gene caused by one germline mutation 
inherited from one parent followed by a somatic second 
inactivating mutation in the wild type allele. Based on the 
pattern of inheritance suggested for FBE [17], it is likely 
that development of familial BE is caused by an inherited 
germline mutation in a (unknown) tumor suppressor gene 
followed by a somatic second inactivating mutation in the 
wild type allele causing biallelic inactivation.
Orloff et al. identified germline mutations in the genes 
MSR1, ASCC1, and CTHRC1 with the use of a linkage 
analysis on affected siblings diagnosed with BE or EAC 
[18]. However, information about the presence of iden-
tical germline mutations in affected siblings is lack-
ing and the role of these genes in the development of 
FBE is unknown. Extensive candidate gene and linkage 
researches have to date been unsuccessful in identifying 
genetic variants that are associated with the risk of FBE.
Here, we describe a family, of whom two members 
were diagnosed with BE and three with EAC. To identify 
a possible germline defect in the affected family mem-
bers, we investigated the normal DNA of a proband with 
a SNP array and exome sequencing. Subsequently, we 
validated the potential germline variants identified in 
the proband in the normal and tumor DNA of the other 
affected family members on a Next-Generation sequenc-
ing platform.
Methods
This study was approved by the Erasmus MC—University 
Medical Center Rotterdam Institutional Review Board. 
Formal written informed consent was obtained from the 
living family members, whom are therefore included in 
the study. All tissues investigated in this study were used 
in accordance with the code for adequate secondary use of 
tissue, code of conduct: “Proper Secondary Use of Human 
Tissue” as established by the Dutch Federation of Medical 
Scientific Societies (http://www.federa.org).
Family presentation
The first family member (further referred to as proband), 
who came to our attention is a male patient of 45 years 
(Fig. 1: II.3). He has been suffering from pyrosis for several 
years and was diagnosed in … with BE (LGD) based on 
histopathological examination of multiple biopsies obtained 
during upper gastrointestinal endoscopy. In addition, in his 
family there is a high incidence of BE and EAC (Fig. 1). His 
father (I.1) was diagnosed, in 1982 at the age of 50 years, 
with EAC based on histopathological examination of mul-
tiple biopsies during upper gastrointestinal endoscopy, 
unfortunately he died in the same year of the consequences 
of the disease (no tissue available). The oldest brother of 
the proband (II.1) was diagnosed with EAC at the age of 
49 years. He underwent neoadjuvant chemoradiotherapy fol-
lowed by an esophagectomy. Pathological examination of the 
resection specimen revealed a vital adenocarcinoma within 
the background of BE (HGD) located at the distal esopha-
gus, Mandard score III–IV, ypT3N0. He died 1 month later 
at the age of 50 years due to post-operative complications. 
At autopsy, liver metastases were identified. Furthermore, 
the older sister of the proband (II.2) was diagnosed with a 
poorly differentiated adenocarcinoma at the gastro-esoph-
ageal junction at the age of 45 years and died 1 year later 
of the consequences of the disease. The younger brother 
of the proband (II.4) has been suffering from pyrosis for 
several years, and was diagnosed with BE (intestinal meta-
plasia, no dysplasia) based on histopathological examination 
of multiple biopsies obtained during upper gastrointestinal 
endoscopy at the age of 40. He was prescribed proton pump 
inhibitors and included in the surveillance program for BE, 
in the biopsies taken during the latest control no intestinal 
metaplasia was observed any longer. The youngest sister of 
Fig. 1  Pedigree of investigated family. Black symbols indicate 
esophageal adenocarcinoma. Partly blocked symbols indicate Bar-
rett esophagus and/or gastro-esophageal reflux (GER). The proband is 
indicated by a red arrow
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the proband (II.5) did not give informed consent, and was 
therefore not included in the study.
SNP array and exome sequencing
The proband (II.3) was subjected to genetic testing, i.e. 
SNP array and exome sequencing performed at the Eras-
mus MC Center for Biomics, Rotterdam, the Netherlands. 
After informed consent was obtained during a counselling 
session at the Department of Clinical Genetics, blood was 
drawn and DNA was isolated using a Chemagic DNA Blood 
Kit according to standard procedures. To identify copy num-
ber variations (CNVs) in the germline DNA of the proband 
(II.3), the Genome-wide human SNP array 6.0 was per-
formed according to the manufacturer’s protocol (Affym-
etrix, Santa Clara, CA, USA). Data were analyzed using 
Nexus Copy Number tm V4 software (Biodiscovery, Haw-
thorne, CA, USA). Exome sequencing was performed on the 
Hiseq2000, using the Agilent version 4 capture kit, accord-
ing to the Illumina TruSeq v3 protocol. Reads were aligned 
against the human reference genome build 19 (hg19) using 
Burrows-Wheeler Aligner [19] and the NARWHAL pipeline 
[20]. Subsequently, genetic variants were called using tools 
from the genome analysis toolkit [21]. The resulting VCF 
files were processed with a custom variant annotation tool 
that determines the variant effects. Germline variants iden-
tified by exome sequencing were selected to cause amino-
acid changes or splice-site alterations, in addition variants 
present in the dbSNP135 database or with a frequency of 
> 1% in ESP6500 and the 1000 Genomes databases were 
excluded. To confirm these data on a different platform, 
a custom-made panel was designed by the Ion AmpliSeq 
Designer V2.0 for targeted sequencing on the Ion Torrent 
Personal Genome Machine (Ion PGM) (Life Technologies, 
Carlsbad, CA, USA). In short, libraries were made using 
the Ion AmpliSeq Library Preparation Kit. A template was 
prepared using the Ion OneTouch Template Kit and sequenc-
ing was performed with the Ion Sequencing Kit v2.0 on an 
Ion 316 chip. Data were analyzed with the Variant Caller 
v2.2.3-31149 (Life Technologies, Carlsbad, CA, USA). For 
the variants that could not be validated by the ion PGM, 
primers were designed for PCR amplification and Sanger 
sequencing on an ABI 3730 sequencer (Life Technologies, 
Carlsbad CA, USA) according to the BigDye Terminator 
v3.1 Cycle Sequencing Kit Protocol. DNA sequences were 
visualized using the Mutation Surveyor software (Softgenet-
ics, State College, PA, USA), which aligned the sequences 
to annotated GenBank reference files.
Tissue samples
To test whether the validated germline variants in the 
proband (II.3) could also be identified in the normal and 
tumor DNA of the family members, formalin-fixed paraffin-
embedded (FFPE) tissue blocks were reclaimed from several 
pathology archives in the Netherlands. Tumor tissue (II.1, 
II.2) composed of at least 50% neoplastic cells (confirmed 
by a GI-pathologist) and areas of non-malignant esophageal 
cells (II.1, II.2, II.4) were manually microdissected from 10 
to 15 hematoxylin-stained sections (4 µm). Subsequently, 
DNA was extracted using proteinase K and 5% Chelex 100 
resin.
Results
The SNP array revealed a known CNV with no clinical rel-
evance and a CNV in an unknown gene (data not shown). 
Exome sequencing performed on the normal DNA of the 
proband (II.3) revealed after the selection procedure 244 
candidate germline variants (Table 1). For 228 variants cus-
tom-made primers could be designed to confirm the data 
on a different platform. After sequencing on the ion PGM, 
206 variants were verified successfully in the normal DNA 
of the proband (II.3). The remaining 22 variants obtained 
either low sequencing depth or poor coverage and therefore 
did not qualify for further analysis on the ion PGM. For the 
38 variants, which could not be validated by the ion PGM, 
primers were designed for PCR amplification and Sanger 
sequencing. Of the 38 variants, six were validated in the 
normal DNA of the proband (II.3) by Sanger sequencing. 
Leaving 212 potential germline variants of interest, which 
were validated in the family members (Fig. 2).
The custom-made panel for the ion PGM, contain-
ing the germline variants identified in the proband (II.3), 
was extended to two other affected members of the fam-
ily (II.1, II.2). Normal DNA of the affected family mem-
bers (II.1, II.2) was analyzed for the presence of the 212 
potential germline variants identified in the proband (II.3). 
In addition, the respective tumors of the family members 
(II.1, II.2) were analyzed for somatic loss of the wild type 
allele or the presence of an inactivating somatic mutation in 
the wild type allele. Twenty-four of the potential germline 
Table 1  Mutations identified in normal DNA of the proband by 
exome sequencing
a Indels insertions and deletions
Amount N = 244 (%)
Non-synonymous 164 (67.2)
Stop gains 3 (1.2)
Frameshift  indelsa 14 (5.7)
Non-frameshift  indelsa 44 (18.0)
Splice-site variants 12 (4.9)
Unknown 7 (2.9)
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variants were also identified in the normal DNA of the fam-
ily members II.1 and II.2. Only one potential germline vari-
ant, MSX1 (chr4: 4,861,985 T > G, c.359T > G, p.V120G, 
NM_002448), showed loss of the wild type allele in both the 
tumor DNA of family members II.1 and II.2. In the normal 
and metaplastic DNA of the youngest brother (II.4) no vari-
ant in MSX1 was identified (Fig. 3).
Discussion
For the first time a germline variant in the MSX1 gene was 
identified in a family with clustering of BE and EAC with 
the aid of exome sequencing. In addition, the investigated 
tumors of two affected family members showed somatic 
loss of the wild type allele. The germline variant in MSX1 
changed codon 120 from Valine into Glycine. Although not 
reported in the Cosmic database and in dbSNP135, the vari-
ant was described before on a very low frequency (allele fre-
quency: 0.00052) [22], suggesting that this is a rare variant. 
This finding indicates that the germline defect in MSX1 may 
be associated with the high occurrence of BE and EAC in 
this Dutch family.
MSX1 encodes a homeobox protein and is involved in 
multiple epithelial-mesenchymal interactions. In addition, 
MSX homeobox genes are able to interact with bone mor-
phogenetic proteins (BMPs), in particular to the closely 
related BMP-2 and BMP-4. Recent studies established e.g. 
BMP-4 signaling as important interconnected regulatory 
pathways that contribute to the early stage of the transfor-
mation of the epithelial cells of the distal esophagus from the 
normal stratified squamous mucosa to an intestinal colum-
nar cell type. BMP-4 was found to be present in inflamed 
squamous epithelium but not in normal squamous mucosa 
[23]. MSX1 may be involved in the malignant progression 
of BE into EAC for familial cases as well as for sporadic 
cases, however somatic mutations in MSX1 were identified 
in a very low frequency by Dulak et al. (p.R158W, p.F151L, 
p.P153P) [24], suggesting a prominent role of this germline 
defect in the development of BE and EAC in this particu-
lar family. In addition, mutations in MSX1 have also been 
reported in families with dominantly inherited congenital 
absence of several permanent teeth, called oligodontia or 
Fig. 2  Flowchart of sequenc-
ing pipeline WES whole exome 
sequencing, Ion PGM Ion Tor-
rent Personal Genome Machine, 
Sanger Sanger sequencing, G 
Germline DNA, T Tumor DNA
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hypodontia, with or without cleft lip and/or palate [25–28], 
no oligodontia or hypodontia was observed in the proband.
In one of the family members (II.4) the MSX1 variant 
was not observed, although he did suffer from pyrosis and 
was diagnosed with intestinal metaplasia at the first histo-
pathological examination. However, the most recent biopsies 
taken during upper gastro-intestinal endoscopy revealed no 
signs of intestinal metaplasia. It can therefore be hypoth-
esized that family member II.4 is a phenocopy. Since the 
prevalence of BE in the common population is estimated at 
2% [29, 30], it can be anticipated that the initial metaplasia 
in this family member developed as a consequence of an 
environmental factor, instead of within the context of an 
inherited genetic defect.
Family member II.3 was indicated as the proband and 
since he was only diagnosed with BE without invasive carci-
noma, it has to be taken into account that MSX1 may only be 
associated with the development of BE and not necessarily 
with EAC. In addition, it was not possible to test the pres-
ence of the MSX1 variant in the father of proband (I.1), also 
diagnosed with EAC, since no tissues blocks were present.
Previous studies introduced and persevered the defini-
tion familial BE, i.e. two or more first- or second-degree 
family members diagnosed with BE, and/or EAC. These 
studies considered familial BE and familial EAC to be 
part of the same genetic trait, because EAC appears to 
arise from BE and both conditions share the same epide-
miologic risk factors. However, one can hypothesize that 
familial EAC can be distinct from most familial BE. Since 
BE is much more prevalent among the common popula-
tion, familial BE does not necessarily have to be the under-
lying condition of familial EAC. Therefore, familial EAC 
might be the result of accelerated malignant progression 
from familial BE, or familial EAC might arise without 
familial BE as the premalignant condition. In both sce-
narios involvement of specific germline mutations driving 
familial EAC can be envisaged. Although, the criteria of 
FBE can be discussed, since this definition was frequently 
used in the literature it was persevered in this study to 
conduct uniformity.
In conclusion, a germline variant in MSX1 was identi-
fied in the normal DNA of three affected members of a 
family with clustering of BE and EAC, in addition the 
investigated tumors showed somatic loss of the wild type 
allele, consistent with biallelic inactivation of a tumor sup-
pressor gene. This germline defect may be associated with 
the development of BE and EAC in this family. However, 
functional studies have to be performed to prove any effect 
of this germline defect.
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Fig. 3  Sanger sequencing results of MSX1. a Sanger sequencing of 
normal DNA of the proband (II.3) confirmed the presence of the het-
erozygote variant (c.359T > G) in MSX1. b Sanger sequencing of nor-
mal DNA of youngest brother of the proband (II.4) revealed no vari-
ant in MSX1. c Sanger sequencing of normal DNA (upper panel) and 
tumor DNA (lower panel) of the oldest brother of the proband (II.1) 
confirmed the presence of the heterozygote variant (C.359T > G) in 
MSX1 in normal DNA and loss of the wild type allele in tumor DNA 
which changed the codon 120 from Valine into Glycine (P.V120G). 
d Sanger sequencing of normal DNA (upper panel) and tumor DNA 
(lower panel) of the older sister of the proband (II.2) confirmed the 
presence of the heterozygote variant (c.359T > G) in MSX1 in normal 
DNA and loss of the wild type allele in tumor DNA, which changed 
the codon 120 from Valine into Glycine (p.V120G)
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